Home Featured Page 3

Featured

Latest

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Victoria Litman – The Future of Psychedelic Regulation Is Local

Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber;...

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

Dreamshadow Transpersonal Breathwork

East Forest IN THE PORTAL DOME

An Ecstatic Dance Experience IN THE PORTAL DOME

Samskara Film & Discussion w/ Android Jones IN THE PORTAL DOME

Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to...

Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major...

Jeff Breau – Exploring Psychedelic Churches at Harvard Divinity School

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar

1 234...291 Page 3 of 291

EDITOR PICKS

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Victoria Litman – The Future of Psychedelic Regulation Is Local

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Victoria Litman – The Future of Psychedelic Regulation Is Local

Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber;...

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

Dreamshadow Transpersonal Breathwork

East Forest IN THE PORTAL DOME

SNOW RAVEN IN THE PORTAL DOME

PORTAL LATE-NIGHT TAKEOVER

An Ecstatic Dance Experience IN THE PORTAL DOME

Samskara Film & Discussion w/ Android Jones IN THE PORTAL DOME

Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to...

Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major...

Jeff Breau – Exploring Psychedelic Churches at Harvard Divinity School

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar

EDITOR PICKS

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Victoria Litman – The Future of Psychedelic Regulation Is Local

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY